Updated Jul 16, 2026 · Last SEC filing 2026-07-08
Enliven Therapeutics, Inc. (ELVN) has filed 8 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-08. 4 Form 8-K material event filings were reported by ELVN in the last 90 days. 10 Form 144 notices of proposed sale were filed for ELVN stock. InsiderAlpha tracks every ELVN SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SIC classification | Pharmaceutical Preparations (SIC 2834) |
|---|---|
| SEC CIK | 0001672619 |
| Form 4 filings (90d) | 8 |
|---|---|
| Form 8-K filings (90d) | 4 |
| Form 144 notices (90d) | 10 |
| Latest Form 4 filing | 2026-07-08 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Kunkel Lori Anne | Insider | S — Open-market sale | 4.1K | $49.98 | $205K | SEC | |
| Kunkel Lori Anne | Insider | S — Open-market sale | 5.9K | $50.84 | $299K | SEC | |
| ORBIMED ADVISORS LLC | 10% Owner | S — Open-market sale | 1.5K | $45.00 | $66K | SEC | |
| ORBIMED ADVISORS LLC | 10% Owner | S — Open-market sale | 24.8K | $45.38 | $1.13M | SEC | |
| ORBIMED ADVISORS LLC | 10% Owner | S — Open-market sale | 46.8K | $45.00 | $2.10M | SEC | |
| ORBIMED ADVISORS LLC | 10% Owner | S — Open-market sale | 787.0K | $45.38 | $35.72M | SEC | |
| Hohl Benjamin | CHIEF FINANCIAL OFFICER | S — Open-market sale | 1.2K | $44.75 | $55K | SEC | |
| Collins Helen Louise | CHIEF MEDICAL OFFICER | M — Option exercise | 5.0K | $2.48 | $12K | SEC | |
| Collins Helen Louise | CHIEF MEDICAL OFFICER | S — Open-market sale | 2.6K | $43.87 | $114K | SEC | |
| Hohl Benjamin | CHIEF FINANCIAL OFFICER | S — Open-market sale | 1.4K | $42.78 | $59K | SEC | |
| Hohl Benjamin | CHIEF FINANCIAL OFFICER | M — Option exercise | 6.0K | $2.48 | $15K | SEC | |
| Hohl Benjamin | CHIEF FINANCIAL OFFICER | S — Open-market sale | 3.4K | $43.86 | $149K | SEC | |
| Collins Helen Louise | CHIEF MEDICAL OFFICER | S — Open-market sale | 1.3K | $42.83 | $54K | SEC | |
| Collins Helen Louise | CHIEF MEDICAL OFFICER | S — Open-market sale | 1.1K | $44.74 | $51K | SEC | |
| ORBIMED ADVISORS LLC | 10% Owner | S — Open-market sale | 9.1K | $45.02 | $409K | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Enliven Therapeutics, Inc. (ELVN). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Collins Helen Louise | 15 | $694K |
| ORBIMED ADVISORS LLC | 6 | $51.68M |
| Hohl Benjamin | 5 | $279K |
| Kunkel Lori Anne | 5 | $850K |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in ELVN insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live ELVN dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.